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Objectives. We investigated immune phenotypes of HIV+ patients who present late, considering late presenters (LPs, CD4+ <
350/μL and/or AIDS), advanced HIV disease (AHD, CD4+ < 200/μL and/or AIDS), and AIDS presenters (AIDS-defining condition
at presentation, independently from CD4+). Methods. Patients newly diagnosed with HIV at our clinic between 2007–2011
were enrolled. Mann-Whitney/Chi-squared tests and logistic regression were used for statistics. Results. 275 patients were newly
diagnosed with HIV between January/2007–March/2011. 130 (47%) were LPs, 79 (29%) showed AHD, and 49 (18%) were AIDS
presenters. LP, AHD, and AIDS presenters were older and more frequently heterosexuals. Higher CD8+%, lower CD127+CD4+%,
higher CD95+CD8+%, CD38+CD8+%, and CD45R0+CD38+CD8+% characterized LP/AHD/AIDS presentation. Inmultivariate
analysis, older age, heterosexuality, higher CD8+%, and lower CD127+CD4+% were confirmed associated with LP/AHD. Lower
CD4+ and higher CD38+CD8+% resulted independently associated with AIDS presentation. Conclusions. CD127 downregulation
and immune activation characterize HIV+ patients presenting late and would be studied as additional markers of late presentation.
1. Introduction
Despite reduced morbidity and mortality achieved by highly
active antiretroviral therapy (HAART) and extensive work
encouraging earlier HIV testing, late presentation of HIV
remains a relevant clinical problem. Up to 15%–38% of HIV
positive patients present late for testing with a low CD4+
T-cell count, high viral load, and severe alterations of their
immune system [1]. Focusing on the Italian scenario, 39%
of new HIV diagnosis occur late [2]. Compared to patients
diagnosed with HIV early in the course of infection, late
presenters are at higher probability of clinical progression
and treatment-related adverse events and introduce HAART
later than recommended by current antiretroviral therapy
guidelines [3, 4]. Furthermore, late presentation deeply
impacts on healthcare system and community in terms of
resource use and higher risk of HIV transmission to sexual
partners [5]. Recently, two diﬀerent classifications of late
presentation have been established by the European AIDS
Clinical Society [6]: all patients who present with a CD4+
T-cell count less than 350 cells/μL and/or an AIDS-defining
condition at, or within a month after, HIV diagnosis are
identified as “late presenters.” This definition allows for
the identification of patients that should be considered for
treatment in accordance with current guidelines. Secondly,
focusing on the established risk cutoﬀ for developing oppor-
tunistic infections, all patients who present with a CD4+ T-
cell count less than 200 cells/μL and/or an AIDS event should
be considered to have “advanced HIV disease” [7, 8].
Previous studies identified the demographic parameters
associated with a high risk of late presentation. Older age,
heterosexual transmission of infection, and foreign birth
(non-White and in particular Black African ethnicity) may
influence the risk of late diagnosis [1–13]. On the contrary,
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a clear association between gender and late HIV testing has
not been recognized [9–14].
As expected, low CD4+ T-cell count at presentation as-
sociates with increased risk of AIDS defining illnesses. The
most commonly diagnosed AIDS conditions are Pneumocys-
tis jiroveci pneumonia and tuberculosis, followed by Cytome-
galovirus infections, toxoplasmosis, and wasting syndrome.
Patients with AIDS at presentation represent a real medical
challenge because of their advanced clinical status and higher
risk of clinical progression and mortality. At least two
clinical challenges relate to these patients and include the
timing of HAART introduction based on the concomitant
opportunistic infections and the elevated risk of failing a
satisfactory CD4+ recovery, even after long-term virological
suppression by HAART [15, 16].
A broad immunological characterization of patients with
a late diagnosis of HIV infection and/or an AIDS disease
at presentation is still lacking. Detailing the alterations of
immune system homeostasis associated to late presentation
would allow for the identification of an early immunological
marker to complement CD4+ T-cell count in the clinical out-
come of late presenter patients; this could be crucial in order
to tailor antiretroviral therapy to individual circumstances of
late presenters.
In this context, the aim of this study is to analyze the
peripheral T lymphocyte phenotypes in patients who were
newly diagnosed with HIV and to determine demographic
and immunological factors associated with late HIV positive
testing, defined in accordance with the two most recent
classifications (late presentation and advanced HIV disease).
2. Materials and Methods
2.1. Study Design and Population. We identified all patients
aged >18 years who were newly diagnosed with HIV at the
Clinic of Infectious Diseases of “S. Paolo” Hospital in Milan,
Italy, between January 2007 and March 2011. Analyses were
restricted to subjects with a new HIV antibody-positive test
and at least one CD4+ T-cell count within 30 days of HIV
diagnosis. Persons with a previous positive HIV test were
excluded from the analysis.
Information on demographic parameters (sex, date of
birth, country of birth) and HIV-related data (HIV exposure
category, calendar period of HIV diagnosis, AIDS event,
CD4+ T-cell count, HIV-RNA, and HCV coinfection) at
presentation were retrospectively collected.
We defined “migrants” patients who were born outside
the European Community (including people from Eastern
Europe, Africa, Asia, and Latin America).
2.2. Definitions of Late Presentation. We used two diﬀerent
definitions of late presentation, in line with the recent indi-
cations by UK Collaborative HIV Cohort (CHIC) study and
HIV in Europe group [6, 7]. Definitions were not mutually
exclusive.
According to the first classification, all patients whose
CD4+ T-cell count at the time of diagnosis was <350 cells/μL
were defined “late presenters” (LPs). Secondly, all patients
who present with a CD4+ T lymphocyte count <200 cells/μL
were considered to have “advanced HIV disease” (AHD). In
all definitions, patients presenting with an AIDS defining
condition were considered as LP and AHD subjects regard-
less CD4+ T-cell count. Patients with an AIDS diagnosis
at presentation (defined according to the 1993 Centers for
Disease Control and Prevention criteria) [17] from 30 days
prior to 30 days after their first positive HIV test were
considered as AIDS presenters.
2.3. T-Cells Immune Phenotypes. Peripheral T lymphocyte
immune phenotypes were recorded for all patients. Lympho-
cyte surface phenotypes were evaluated by flow cytometry
on fresh peripheral blood (Coulter ESP; Beckman Coulter,
Hialeah, Fla) using the following fluorochrome-labelled
antibodies: CD4-Pcy7, CD8-Pcy5, CD38-FITC, CD45-ECD,
CD45R0-PE, CD95-FITC, and CD127-PE. Percentages of
each T-cell subpopulations were calculated on whole lym-
phocyte population. We evaluated activation (expression
of CD45R0 and CD38 on CD8+), sensitivity to Fas-
mediated cells death (expression of CD95 on CD4+ and
CD8+), and IL-7 receptor (CD127) expression on CD8+
and CD4+ T cells. The following combinations were
used: CD8/CD38, CD8/CD38/CD45R0, CD8/CD4/CD95,
and CD8/CD4/CD127.
2.4. Statistical Analysis. Continuous variables were expressed
as median and interquartile range (IQR), categorical vari-
ables as absolute numbers and percentages. Baseline diﬀer-
ences between LPs, and nonlate presenters (N-LPs, patients
with CD4+ T-cell count ≥350 cells/μL and without an
AIDS diagnosis at presentation), between AHD subjects
and patients who did not display advanced HIV disease
(N-AHD, CD4+ T-cell count ≥200 cells/μL and without
an AIDS event at presentation), and finally between AIDS
presenters and patients asymptomatic for AIDS diseases at
presentation (N-AIDS presenters) were assessed using the
Mann-Whitney nonparametric U-test and the Chi-squared
test for continuous and categorical variables, respectively.
In addition, we performed further analyses using N-LP
as unique comparison group.
Multivariate logistic regression models were used to
identify baseline peripheral immune phenotypes that were
independently associated with LP, AHD, or AIDS presen-
tation. T lymphocyte phenotypes with a P value ≤0.05 in
the univariate analyses entered the final multivariate models.
Each final model was adjusted for potential confounders:
the models were adjusted for the demographic parameters
that resulted significantly associated with the outcome in the
univariate analysis.
Analyses were performed using SPSS software (version
18.01). A P value ≤0.05 was considered to denote statistical
significance.
3. Results
3.1. Baseline Characteristics of the Study Population. During
the study period (January 2007–March 2011), 275 patients
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Table 1: (a) Demographic and immunovirological characteristics
of study population. (b) Peripheral T lymphocyte immune pheno-
types of study population.
(a)
Characteristics Patients (N = 275)
Age, years∗ 37 (31–46)
Gender, male◦ 225 (82)
Risk group◦
Homosexual 152 (55)
Heterosexual 111 (40)
IDUs 10 (4)
Other 2 (1)
Migrants◦ 73 (26)
HCV coinfection◦ 16 (6)
Calendar year of presentation◦
2007 85 (31)
2008 61 (22)
2009 61 (22)
2010 61 (22)
January–March 2011 7 (3)
AIDS presenters◦ 49 (18)
HIV-RNA log10 cp/mL∗ 4.37 (2.78–5.16)
CD4+ T cells/μL∗ 396 (234–555)
(b)
T-cells immunophenotypes Patients (N = 275)
CD4 T cells %∗ 22 (14–30)
CD8 T cells %∗ 51 (42–60)
CD4+CD127+ cells %∗ 12 (7–20)
CD8+CD127+ cells %∗ 11 (8–17)
CD4+CD95+ cells %∗ 2 (1–4)
CD8+CD95+ cells %∗ 2 (1–4)
CD8+CD38+ cells %∗ 6 (3–12)
CD8+CD38+CD45R0+ cells %∗ 12 (7–20)
Data are presented as ∗median, (interquartile range, IQR) and ◦absolute
number, (%). IDUs: injection drug users; migrants: people who were
born outside the European community (including people from Eastern
Europe, Africa, Asia, and Latin America); HCV: hepatitis C virus.
were diagnosed for the first time with HIV infection at our
clinic. Characteristics of the 275 subjects at presentation are
summarized in Table 1.
Overall, the majority of patients were male (225/275,
82%) with a median age of 37 (IQR 31–46) years and
acquired HIV infection mostly through sexual contacts
(homosexual transmission 152/275, 55%—heterosexual
transmission 111/275, 40%) (Table 1(a)).
A total of 16 (6%) patients displayed HCV coinfection.
Most subjects were of white ethnicity, while 73 (26%) HIV-
positive patients were born outside the European commu-
nity.
The proportion of new HIV diagnosis remained stable
over time (31% in 2007, 22% in 2008-2009-2010).
3.2. Immunovirological Parameters of the Study Population.
Median CD4+ count at first presentation for HIV care
was 396 cells/μL (IQR 234–555), and median viral load was
4.37 log10 cp/mL (IQR 2.78–5.16). The other percentages
(median, IQR) of peripheral T lymphocytes immune phe-
notypes were reported in Table 1(b).
3.3. Characteristics of Late Presenters. 130 (47%) patients
showed CD4+ T-cell counts <350 cells/μL and/or an AIDS
defining event at presentation and were classified as late
presenters (LPs) (Table 2). Compared to N-LPs, LPs were
older (median age: LP 41, IQR 34–50—N-LP 36, IQR
30–43 years; P = 0.0001), contracted HIV infection
more frequently through heterosexual contacts (heterosexual
transmission: LP 64, 49%—N-LP 47, 32%; homosexual
transmission: LP 59, 45%—N-LP 93, 64%; intravenous drug
users: LP 6, 5%—N-LP 4, 3%; P = 0.020), and resulted
more commonly migrants (LP 43, 33%—N-LP 30, 21%; P =
0.020). No diﬀerences were observed between the two groups
of patients regarding gender, coinfections, and calendar year
of presentation (Table 2(a)).
Interestingly, analyzing the immune phenotypes of pe-
ripheral T lymphocytes, we found that LP were character-
ized by a significantly diﬀerent immunological pattern in
comparison to N-LP. In particular, LP displayed higher
CD8+ T-cells percentages (LP 57, IQR 51–63—N-LP 45,
IQR 38–54; P = 0.0001), lower IL-7 receptor (CD127) expres-
sion on CD4+ T cells (median CD127+CD4+%: LP 7,
IQR 4–12—N-LP 19, IQR 12–24; P = 0.0001), and higher
expression of CD95 receptor (median CD95+CD8+%: LP 3,
IQR 2–5—N-LP 2, IQR 1–3; P = 0.0001), activated CD38+
(median CD38+CD8+%: LP 9, IQR 3–18—N-LP 5, IQR 2–
9; P = 0.0001) and terminal-diﬀerentiated CD45R0+CD38+
(median CD45R0+CD38+CD8+%: LP 15, IQR 10–25—N-
LP 9, IQR 5–16; P = 0.0001) on CD8+ T cells. The other
immune phenotypes did not result significantly diﬀerent
between LP and N-LP (Table 2(b)).
3.4. Characteristics of Patients Presenting Advanced HIV
Disease. Using the second criteria to identify patients with
a new diagnosis of HIV infection in a late stage of disease,
79 (29%) subjects presented advanced HIV disease (AHD)
(Table 3). Similarly to the first definition, AHD patients
resulted older (median age: AHD 42, IQR 34–52—N-AHD
36, IQR 31–44; P = 0.0001) andmore frequently heterosexual
(heterosexual transmission: AHD 41, 52%—N-AHD 70,
36%; homosexual transmission: AHD 34, 43%—N-AHD
118, 60%; intravenous drug users: AHD 4, 5%—N-AHD
6, 3%; P = 0.044). The proportion of HIV/HCV coinfection
and migrants were comparable between the two groups of
patients; in parallel, from 2007 to the first months of 2011,
we did not register a substantial decrease of late diagnosis
(Table 3(a)).
Diverse immune phenotype patterns were detected in
AHD and N-AHD patients: AHD presented higher CD8+
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Table 2: (a) Analysis of the association of demographic and HIV-related characteristics with late presentation. (b) Analysis of the association
of T-cells subpopulations with late presentation.
(a)
Parameters
Late presenters (CD4 T cell < 350 and/or AIDS defining event)
P
No (145, 53%) Yes (130, 47%)
Age, years∗ 36 (30–43) 41 (34–50) 0.0001
Gender, male◦ 120 (83) 105 (81) 0.669
Risk group◦ 0.020
Homosexual 93 (64) 59 (45)
Heterosexual 47 (32) 64 (49)
IDUs 4 (3) 6 (5)
Other 1 (1) 1 (1)
Migrants◦ 30 (21) 43 (33) 0.020
HCV coinfection◦ 7 (5) 9 (7) 0.382
Calendar year of presentation◦ 0.385
2007 52 (36) 33 (25)
2008 32 (22) 29 (22)
2009 30 (21) 31 (24)
2010 28 (19) 33 (25)
January–March 2011 3 (2)
HIV-RNA log10 cp/mL∗ 4.33 (3.24–4.96) 4.54 (1.77–5.26) 0.884
CD4+ T cells/μL∗ 538 (441–698) 218 (100–290) 0.0001
(b)
T-cells immunophenotypes
Late Presenters (CD4 T cell < 350 and/or AIDS defining event)
P
No (145, 53%) Yes (130, 47%)
CD4+ T cells %∗ 28 (23–35) 14 (10–21) 0.0001
CD8+ T cells %∗ 45 (38–54) 57 (51–63) 0.0001
CD4+CD127+ cells %∗ 19 (12–24) 7 (4–12) 0.0001
CD8+CD127+ cells %∗ 10 (8–15) 11 (7–19) 0.346
CD4+CD95+ cells %∗ 2 (1–4) 2 (1–3) 0.898
CD8+CD95+ cells %∗ 2 (1–3) 3 (2–5) 0.0001
CD8+CD38+ cells %∗ 5 (2–9) 9 (3–18) 0.0001
CD8+CD38+CD45R0+ cells %∗ 9 (5–16) 15 (10–25) 0.0001
Data are presented as ∗median, (interquartile range, IQR) and ◦absolute number, (%). IDUs: injection drug users; migrants: people who were born outside
the European community (including people from Eastern Europe, Africa, Asia, and Latin America); HCV: hepatitis C virus.
Comparison between categorical variables was assessed by Pearson’s Chi square and between continuous variables by nonparametric Mann-Whitney U-test.
P < 0.05 was considered to denote statistical significance.
(AHD: 59, IQR 51–66—N-AHD 48, IQR 41–57; P = 0.0001),
lower CD127+CD4+ (median CD127+CD4+%: AHD 6,
IQR 3–11—N-AHD 15, IQR 10–22; P = 0.0001), higher
CD95+CD8+ (median CD95+CD8+%: AHD 3, IQR 2–6—
N-AHD 2, IQR 1–3; P = 0.0001), CD38+CD8+ (median
CD38+CD8+%: AHD 11, IQR 3–25—N-AHD 5, IQR
2–10; P = 0.0001), and CD45R0+CD38+CD8+ (median
CD45R0+CD38+CD8+%: AHD 14, IQR 10–25—N-AHD
11, IQR 7–19; P = 0.008) percentages in comparison to N-
AHD (Table 3(b)).
3.5. AIDS Presenters. An AIDS defining condition was re-
ported for 49/275 (18%) subjects with a new HIV diag-
nosis during the study period. The most common diseases
were Kaposi’s Sarcoma (12/49, 24%), Pneumocystis jiroveci
pneumonia (8/49, 16%), and tuberculosis (7/49, 14%).
Other AIDS-related illnesses were CMV infection (sepsis,
chorioretinitis, and colitis, 4/49, 8%), neurological diseases
(HIV-associated dementia, “HAD,” progressive multifocal
leukoencephalitis, “PML,” and neurotoxoplasmosis, 7/49,
14%), lymphomas (4/49, 8%), esophageal candidiasis (3/49,
7%), Wasting syndrome (3/49, 7%), and cervical cancer
(1/49, 2%).
AIDS presenters weremore frequently older (median age:
AIDS presenters: 42, IQR 35–52—N-AIDS presenters 37,
IQR 31–44; P = 0.0001), male (AIDS presenters: male 45,
92%—female 4, 8%; N-AIDS presenters: male 180, 80%—
female 46, 20%; P = 0.045), and heterosexuals (heterosexual
transmission: AIDS presenters 29, 59%—N-AIDS presen-
ters 82, 36%; homosexual transmission: AIDS presenters
AIDS Research and Treatment 5
Table 3: (a) Analysis of the association of demographic and HIV-related characteristics with advanced HIV disease at presentation. (b)
Analysis of the association of T-cells subpopulations with advanced HIV disease at presentation.
(a)
Parameters
Advanced HIV disease at presentation
P(CD4 T cell < 200 and/or AIDS defining event)
No (196, 71%) Yes (79, 29%)
Age, years∗ 36 (31–44) 42 (34–52) 0.0001
Gender, male◦ 158 (81) 67 (85) 0.414
Risk group◦ 0.044
Homosexual 118 (60) 34 (43)
Heterosexual 70 (36) 41 (52)
IDUs 6 (3) 4 (5)
Other 2 (1) 0
Migrants◦ 50 (26) 23 (29) 0.540
HCV coinfection◦ 10 (5) 6 (11) 0.304
Calendar year of presentation◦ 0.136
2007 63 (32) 22 (28)
2008 40 (20) 21 (26)
2009 50 (25) 11 (14)
2010 39 (20) 22 (28)
January–March 2011 4 (3) 3 (4)
HIV-RNA log10 cp/mL∗ 4.31 (3.17–4.99) 4.68 (1.77–5.37) 0.437
CD4+ T cells/μL∗ 460 (340–614) 110 (56–192) 0.0001
(b)
T-cells immune phenotypes
Advanced HIV disease at presentation
P(CD4 T cell < 200 and/or AIDS defining event)
No (196, 71%) Yes (79, 29%)
CD4+ T cells %∗ 26 (20–32) 10 (7–17) 0.0001
CD8+ T cells %∗ 48 (41–57) 59 (51–66) 0.0001
CD4+CD127+ cells %∗ 15 (10–22) 6 (3–11) 0.0001
CD8+CD127+ cells %∗ 10 (8–15) 12 (8–22) 0.05
CD4+CD95+ cells %∗ 2 (1–4) 2 (1–3) 0.713
CD8+CD95+ cells %∗ 2 (1–3) 3 (2–6) 0.0001
CD8+CD38+ cells %∗ 5 (2–10) 11 (3–25) 0.0001
CD8+CD38+CD45R0+ cells %∗ 11 (7–19) 14 (10–25) 0.008
Data are presented as ∗median, (Interquartile Range, IQR) and ◦absolute number, (%). IDUs: injection drug users; migrants: people who were born outside
the European community (including people from Eastern Europe, Africa, Asia, and Latin America); HCV: hepatitis C virus.
Comparison between categorical variables was assessed by Pearson’s Chi square and between continuous variables by nonparametric Mann-Whitney U test.
P < 0.05 was considered to denote statistical significance.
17, 35%—N-AIDS presenters 135, 60%; intravenous drug
users: AIDS presenters 3, 6%—N-AIDS presenters 7, 3%;
P = 0.044), compared to N-AIDS presenters (226 subjects).
Comparing immune phenotypes between AIDS
presenters and N-AIDS presenters, we observed that AIDS
presenters were associated with lower CD4+ T-cell count
(median CD4+ cells/μL: AIDS presenters 132, IQR 60–286—
N-AIDS presenters 438, IQR 286–583; P = 0.0001), and
higher CD8+ T cells (median CD8+%: AIDS presenters 59,
IQR 50–66—N-AIDS presenters 49, IQR 42–59; P = 0.0001).
AIDS presenters featured lower CD127+CD4+%
(median CD127+CD4+%: AIDS presenters 6, IQR 4–
11—N-AIDS presenters 14, IQR 8–21; P = 0.0001),
higher CD95+CD8+% (median CD95+CD8+%: AIDS
presenters 3, IQR 2–6—N-AIDS presenters 1, IQR 2–
4; P = 0.003), CD38+CD8+% (median CD38+CD8+%:
AIDS presenters 12, IQR 5–23—N-AIDS presenters 6,
IQR 2–11; P = 0.0001), and CD45R0+CD38+CD8+%
(median CD45R0+CD38+CD8+%: AIDS presenters 16,
IQR 10–25—N-AIDS presenters 11, IQR 7–19; P = 0.02).
3.6. Factors Independently Associated with Late Presentation.
Given that LPs were distinguished by a peculiar periph-
eral immune phenotype, we investigated the association
between T lymphocyte patterns and late presentation, con-
trolling for potentially confounding factors. We performed
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a logistic regression model (Table 4) including the periph-
eral immune phenotypes that resulted significantly associ-
ated with LP in the univariate analysis (CD8+%, CD4+
CD127+%, CD8+CD95+%, CD8+CD38+%, and CD8+
CD38+CD45R0+%) (Table 2(b)), mutually adjusting for
demographic factors (age, exposure category for HIV,
ethnicity). Higher CD8+ T-cell percentages (AOR 1.051
for each unit more, 95%CI 1.022–1.080, P = 0.0001) and
lower CD127+ expression on CD4+ cells (AOR 0.887 for
each unite more, 95%CI 0.857–0.919, P = 0.0001) resulted
significantly associated with late presentation, independently
of demographic factors.
As expected, also demographic factors were significantly
and independently associated with late presentation; in
fact, older age (AOR 1.052 for each year more, 95%CI
1.020–1.086, P = 0.001), heterosexual acquisition of infection
(AOR 2.435 versus other risk groups, 95%CI 1.251–4.741,
P = 0.009), and non-White race (AOR 2.543 versus white
ethnicity, 95%CI 1.178–5.486, P = 0.017) were associated
with higher risk of delayed HIV testing.
3.7. Factors Independently Associated with Advanced HIV
Disease. To identify possible factors associated with AHD,
significant T-cells immune phenotypes in the univariate
analysis (CD8+%, CD4+CD127+%, CD8+CD95+%, CD8+
CD38+%, and CD8+CD38+CD45R0+%) (Table 3(b)) were
entered in a logistic regression model, mutually adjusted for
age and risk group (Table 5).
The immune phenotypes independently associated with
AHD, after controlling for age and risk groups, were higher
CD8+% (AOR 1.051 for each unit more, 95%CI 1.022–1.081,
P = 0.001), lower CD127+CD4+% (AOR 0.909 for each unit
more, 95%CI 0.878–0.942, P = 0.0001), and, in this case, also
higher-activated CD38+CD8+% (AOR 1.065 for each unit
more, 95%CI 1.020–1.112, P = 0.004) and lower terminal-
diﬀerentiated CD45R0+CD38+CD8+% (AOR 0.955 for each
unit more, 95%CI 0.916–0.996, P = 0.032). AHD patients
were confirmed again significantly characterized by older
age than N-AHD subjects (AOR 1.040 for each year more,
95%CI 1.010–1.071, P = 0.008).
3.8. Factors Independently Associated with AIDS Presentation.
To explore eventual immune phenotypes specifically
characterizing patients with an AIDS-defining pathology
at new diagnosis of HIV, we also conducted a multivar-
iate logistic regression analysis considering AIDS presen-
tation (Table 6). Also, in this case, the parameters with a P
value ≤0.05 in the univariate analysis entered the logistic
regression model: the covariates were CD4+%, CD8+%,
CD4+CD127+%, CD8+CD95+%, CD8+CD38+%, and
CD8+CD38+CD45R0+%, and the model was adjusted for
age, gender, and risk group.
The immunological patterns associated with AIDS pres-
entation independently of demographic factors were of
course lower CD4+% T cells (AOR 0.996 for each unit
more, 95%CI 0.993–0.998, P = 0.008) but also higher
CD38+CD8+% (AOR 1.049 for each unit more, 95%CI
1.004–1.096, P = 0.033). In addition, AIDS presenters were
confirmed significantly associated with heterosexual risk
group (AOR 4.555 versus other risk categories, 95%CI 1.937–
10.711, P = 0.001) and male gender (AOR 9.369 versus
female, 95%CI 2.401–36.551, P = 0.001).
3.9. Comparison between AHD Subjects/AIDS Presenters and
N-LP. We further compared the 79 AHD subjects and
49 AIDS presenters each with the 145 N-LP (comparison
group).
AHD patients and AIDS presenters resulted older
(median age: N-LP 36, IQR 30–43 versus AHD 42, IQR
34–52, P = 0.0001; versus AIDS presenters 42, IQR 35–
52, P = 0.0001) and more frequently heterosexually infected
(heterosexuals: N-LP 47, 32% versus AHD 41, 52%,
P = 0.016; versus AIDS presenters 29, 59%, P = 0.003) in
comparison to N-LP (see Supplementary Material Table 1
available online at doi: 10.1155/2012/314849).
As concern peripheral T lymphocyte immune pheno-
types, compared to N-LP, AHD patients and AIDS presenters
were characterized by higher CD8+% (NLP: 45, 38–45 versus
AHD: 59, 51–66, P = 0.0001; versus AIDS presenters: 59,
50–66, P = 0.0001), lower CD127+CD4+% (NLP: 19, 12–24
versus AHD: 6, 3–11, P = 0.0001; versus AIDS presenters: 6,
4–11, P = 0.0001), higher CD95+CD8+% (NLP: 2, 1–3 versus
AHD: 3, 2–6, P = 0.0001; versus AIDS presenters: 3, 2–6,
P = 0.0001), CD38+CD8+% (NLP: 5, 2–9 versus AHD: 11, 3–
25, P = 0.0001; versus AIDS presenters: 12, 5–23, P = 0.0001),
and CD45R0+CD38+CD8+% (NLP: 9, 5–16 versus AHD:
14, 10–25, P = 0.0001; versus AIDS presenters: 16, 10–25,
P = 0.0001) (Supplementary Table 1).
Finally, we performed two diﬀerent logistic regression
models to assess eventual independent markers of AHD and
AIDS presentation, respectively, always using N-LP as the
unique comparison group.
Interestingly, CD8+% (AOR 1.061 for each unit more,
95%CI 1.031–1.093, P = 0.0001), CD8+CD38+% (AOR
1.066 for each unit more, 95%CI 1.009–1.126, P = 0.022),
CD8+CD38+CD45R0+% (AOR 0.955 for each unit more,
95%CI 0.993–0.997, P = 0.0001), and CD4+CD127+%
(AOR 0.837 for each unit more, 95%CI 0.792–0.884,
P = 0.0001) were significantly associated with AHD, also
after controlling for age and risk groups for HIV infection
(Supplementary Table 2).
Indeed, AHD subjects were confirmed older than N-
LP (AOR 1.051 for each year more, 95%CI 1.012–0.976,
P = 0.010) also in the multivariate analysis (Supplementary
Table 2).
Similarly, we observed an independent association be-
tween AIDS presentation and CD8+CD38+% (AOR 1.078
for each unit more, 95%CI 1.015–1.146, P = 0.015), CD8+
CD38+CD45R0+% (AOR 0.996 for each unit more, 95%CI
0.994–0.999, P = 0.004), and CD4+CD127+% (AOR 0.827
for each unit more, 95%CI 0.759–0.902, P = 0.0001). Also,
this model was adjusted for age and exposure category for
HIV transmission, and, as expected, for each year more of
age (AOR 1.065 for each year more, 95%CI 1.019–1.113,
P = 0.005) and for heterosexual transmission (AOR 3.176
versus other risk categories, 95%CI 1.182–8.531, P = 0.022),
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Table 4: Multivariate logistic regression analysis of the association of demographic and HIV-related characteristics with late presentation.
Late presenters
P(CD4 T cell < 350 and/or AIDS-defining event)
AOR 95% CI
(a) Patients’ factors
Age, years 1.052 1.020–1.086 0.001
Risk group◦
Heterosexual 2.435 1.251–4.741 0.009
Other reference
Ethnicity 0.017
Migrants 2.543 1.178–5.486
Non-migrants reference
(b) T-cells immune phenotypes
CD8+ T cells/μL % (each unit more) 1.051 1.022–1.080 0.0001
CD4+CD127+ cells/μL % (each unit more) 0.887 0.857–0.919 0.0001
CD8+CD95+ cells/μL % (each unit more) 0.993 0.874–1.129 0.919
CD8+CD38+ cells/μL % (each unit more) 1.038 0.989–1.089 0.132
CD8+CD38+CD45R0+ cells/μL % (each unit more) 1.003 0.962–1.045 0.893
AOR: adjusted odds ratio; 95% CI, 95% confidence interval. P < 0.05 was considered to denote statistical significance.
Other: homosexual, intravenous drug users, and other risks groups.
Table 5:Multivariate logistic regression analysis of the association of demographic andHIV-related characteristic with advancedHIV disease
at presentation.
Advanced HIV disease at presentation
P(CD4 T cell < 200 and/or AIDS-defining event)
AOR 95% CI
(a) Patient factors
Age, years 1.040 1.010–1.071 0.008
Risk group◦
Heterosexual 1.788 0.901–3.546 0.096
Other reference
(b) T-cells immune phenotypes
CD8+ T cells/μL % (each unit more) 1.051 1.022–1.081 0.001
CD4+CD127+ cells/μL % (each unit more) 0.909 0.878–0.942 0.0001
CD8+CD95+ cells/μL % (each unit more) 1.063 0.841–1.200 0.327
CD8+CD38+ cells/μL % (each unit more) 1.065 1.020–1.112 0.004
CD8+CD38+CD45R0+ cells/μL % (each unit more) 0.955 0.916–0.996 0.032
AOR: adjusted odds ratio; 95% CI, 95% confidence interval. P < 0.05 was considered to denote statistical significance.
Other: homosexual, intravenous drug users, and other risks groups.
we reported a significant increase of risk of AIDS presenta-
tion.
4. Discussion
In our clinic, we observed 275 new HIV diagnosis in the
period 2007–2011 with no significant diﬀerences over time.
Still nowadays, the greatest percentages of persons diagnosed
with HIV/AIDS are men, of minority ethnicity, and have
as principal HIV transmission risk factor sexual contacts.
Globally, in our experience, patients who present a new HIV-
positive test display a median CD4+ T cells at presentation
of 396 cells/μL and, therefore, near the minimum CD4+
count threshold for initiation of HAART, as suggested by
the most recent international guidelines [6, 18–20]. In fact,
diﬀerent studies have demonstrated that initiating therapy at
CD4+ levels higher than 350 cells/μL improves survival [21].
Furthermore, patients with a CD4+ count between 350 and
500 cells/μL and a HIV-RNA >100.000 copies/mL should be
considered for treatment [6]. For this reason, encouraging
an earlier recourse to HIV testing and access to care becomes
crucial.
Across Europe, many patients still present late in the
course of infection [2]. A universal standard definition of
late presentation has not still found, even if a common
classification could facilitate cross-country comparisons,
identification of risk factors for late testing in diﬀerent
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Table 6: Multivariate logistic regression analysis of the association of demographic and HIV-related characteristic with AIDS presentation.
AIDS presentation (AIDS-defining condition at,
Por within one month after, HIV diagnosis)
AOR 95% CI
(a) Patient factors
Age, years 1.015 0.982–1.050 0.374
Gender◦ 0.001
Male 9.369 2.401–36.551
Female reference
Risk group◦
Heterosexual 4.555 1.937–10.711 0.001
Other reference
(b) T-cells immune phenotypes
CD4+ T cells/μL % (each unit more) 0.996 0.993–0.998 0.002
CD8+ T cells/μL % (each unit more) 0.977 0.931–1.026 0.356
CD4+CD127+ cells/μL % (each unit more) 0.963 0.891–1.042 0.349
CD8+CD95+ cells/μL % (each unit more) 0.994 0.874–1.130 0.922
CD8+CD38+ cells/μL % (each unit more) 1.049 1.004–1.096 0.033
CD8+CD38+CD45R0+ cells/μL % (each unit more) 1.002 0.956–1.052 0.923
AOR: adjusted odds ratio; 95% CI, 95% confidence interval. P < 0.05 was considered to denote statistical significance.
Other: homosexual, intravenous drug users, and other risks groups.
settings and trends in the rate of late presentation over
time. A recent work by UK Collaborative Cohort (UK
CHIC) has proposed two definitions: “late presentation”
(LP), presentation when CD4+ cell count is below the
limit of antiretroviral therapy introduction (current CD4+ <
350 cells/μL and/or a clinical AIDS event at HIV diagnosis);
“advanced HIV disease” (AHD), presentation associated
with a substantial increase in clinical progression/death risk
(current CD4+ < 200 cells/μL and/or AIDS event) [7].
In our study, we reported a prevalence of 47% of LP and
29% of AHD, in line with recent Italian surveys [22, 23].
Regarding demographic parameters associated with LP and
AHD, we confirm that older age and foreign birth outside
European community are risk factors for late HIV testing,
as already widely demonstrated in previous studies [13].
Indeed, LP and AHD were more frequently heterosexuals,
even if absolute numbers of homosexual people presenting
late remain high because of the high prevalence of homo-
sexuals among those HIV infected [22–25]. We observed few
cases of LP/AHD among intravenous drug users (IDUs): this
scenario is confirmed by other Italian studies that did not
find an association between late presentation, and IDUs [11].
On the contrary, in other European works, the proportion
of IDUs who were diagnosed for HIV infection late reached
38.7%, but this diﬀerence could reflect dissimilar screening
policies among IDUs [26].
We did not observe diﬀerences in gender between
LP/AHD and N-LP/N-AHD: in literature, there are some
works that found an association between males and late
HIV testing, while others described an increased risk of late
presentation in women, particularly migrants [11, 14, 15].
We also recorded a high but stable proportion of
LP/AHD in the study period (2007–2011); previous literature
reports described the same temporal trends [27], but other
studies conducted on larger population observed a decline in
the numbers of patients presenting with advanced disease in
2000–2010 [28].
We then focused our attention on the immunological
phenotype of T lymphocytes in peripheral blood associated
with late presentation. As expected, we found that LP and
AHD were characterized by higher percentages of CD8+
T cells, also in the multivariate analysis. It is known that
during HIV infection, persistent viral replication determines
immune perturbation with high levels of CD8+ T-cells acti-
vation/turnover [29]. Interestingly, LP/AHD also displayed
significantly lower percentages of CD127 on the CD4+ pool.
The expression of interleukin- (IL-) 7 receptor (CD127,
IL-7R) and the activity of IL-7/CD127 system are central
for the generation, survival, and diﬀerentiation of naı¨ve
and central memory T cells; in fact, perturbations in this
system are linked to faster disease progression in acute
and chronic HIV infection [30, 31]. Downregulation of IL-
7R is also associated with T-cell activation and immune
recovery following HAART [32]; we recently described that
CD127 expression on CD4+ T cells was the only marker
associated with a reduced risk of incomplete immune
response under HAART [33]. Loss of IL-7R on T cells seems
to determine an impairment of these cells to response to IL-
7 with subsequent inability to diﬀerentiation or reversion
to resting central memory phenotype and a generalized
immune activation with increased susceptibility to apoptosis
[29]. In fact, LP and AHD subjects were characterized
also by higher CD8+ expression of the death receptor Fas
(CD95+), activated CD38+CD8+ T cells, and terminally
diﬀerentiated CD45R0+CD38+CD8+ T cells, compared to
N-LP and N-AHD. It has been previously demonstrated how
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CD38+CD8+ phenotype has predictive value for progression
to AIDS, even after adjustment for CD4+ levels, and it has
been proposed as surrogate marker to clinical monitoring of
HIV infection [34, 35]. Again, in our previous work [33],
the proportion of CD38+CD8+ T cells resulted a feature of
patients introducing late HAART together with higher levels
of CD8+ cells with increased vulnerability to apoptosis (i.e.,
CD95+) and lower CD127+CD4+ T cells. Indeed, increased
numbers of primed activated CD8+CD38+CD45R0+ T cells
have been shown to predict the decline of CD4+ T cells in
HIV-1-infected patients [36, 37] and can be considered a
marker of immune exhaustion reflecting a history of elevated
rounds of proliferation [38]. Although Fas expression on
peripheral T cells are not indicative of an active apoptotic
process, we believe that our data suggest an increased sen-
sitivity of circulating CD8+ T lymphocytes to Fas-mediated
cells death.
On the basis of previous literature findings, we could
hypothesise that HIV-infected patients with a first HIV
diagnosis late in the course of infection display a highly dys-
regulated immunity with expansion of activated/senescent T-
cell phenotypes and contraction of central memory cells; in
this context, loss of CD127 on T cells following immune acti-
vation determines a proapoptotic signal with reinforcement
of CD4 declining and disease progression.
Furthermore, multivariate analysis confirmed reduction
of CD127 on CD4+ T cells as the main marker of late
presentation; given the positive eﬀects of IL-7 on homeostatic
survival and proliferation of T cells, lower CD127+CD4+
percentages could be used as additional marker, together
with CD4+ counts, to identify HIV-positive patients in a
particular advanced stage of disease and at higher risk of
clinical progression and death.
Finally, we studied the demographic factors and immune
phenotypes characterizing patients presenting with AIDS-
defining conditions. Among LP/AHD, the proportion of
AIDS presenters has increased over time and the immuno-
logical status at presentation is severely compromised with a
CD4+ count frequently <50 cells/μL [3]. Overall, also in our
population, almost 20% (49/275, 18%) of patients were AIDS
presenters. As expected, they were older and more frequently
heterosexuals than patients without an AIDS event. In this
case, patients with AIDS resulted also more commonly male,
but globally our population presented a higher prevalence of
male subjects.
From an immunological standpoint, these patients
showed again a deeply compromised immune system: in
addition to lower CD4+ and higher CD8+ levels, we observe
a downregulation of CD127 on CD4+ T cells, higher ex-
pression of CD95+ on CD8+ T cells and higher activated
CD38+CD8+, and terminal-diﬀerentiated CD45R0+CD38+
CD8+ T cells, probably reflecting the same perturbations of
immunological homeostasis registered in late presentation.
In multivariate analysis, however, besides declining CD4+
cells, the main association with AIDS presentation was the
presence of higher immune activation, consistent with the
notion that in AIDS patients a profound immunodeficiency
strongly correlates with generalized immune activation.
5. Conclusion
A broader definition of immunological features of late
presenters could permit a better identification of patients
subsets at high risk of clinical progression and reduced
immunological response to HAART. Besides CD4+ levels,
CD127+ expression on CD4+ T lymphocytes, and T-cell
activation could be proposed as novel additional markers of
late presentation and advanced HIV disease. Further studies
on larger population are needed to confirm immunological
patterns associated with late presentation.
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